Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
USA patent granted for DOSEmapper™ TLD bead strings & Automated Reader.
TRUEinvivo's DOSEmapper™ technology receives enthusiastic feedback from industry leaders at ESTRO37 conference.
TRUEinvivo named finalist in Surrey Business Awards for Business Innovation of the Year, recognizing DOSEmapper™ technology
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
